Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study | Frontline Gastroenterology

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

CME/CPD

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Colorectal

Original research

Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study

Online download statistics by month:

Online download statistics by month: April 2022 to September 2024

	Abstract	Full	Pdf
Apr 2022	144	7	6
May 2022	524	18	34
Jun 2022	274	22	26
Jul 2022	350	20	25
Aug 2022	117	5	12
Sep 2022	181	14	19
Oct 2022	787	66	42
Nov 2022	674	49	43
Dec 2022	349	30	20
Jan 2023	386	24	24
Feb 2023	440	20	21
Mar 2023	334	17	13
Apr 2023	339	23	23
May 2023	371	155	45
Jun 2023	205	25	8
Jul 2023	121	75	39
Aug 2023	86	86	21
Sep 2023	90	89	27
Oct 2023	64	65	20
Nov 2023	99	95	26
Dec 2023	81	82	44
Jan 2024	107	97	31
Feb 2024	77	58	33
Mar 2024	111	96	70
Apr 2024	102	99	39
May 2024	128	96	19
Jun 2024	95	79	30
Jul 2024	350	6	4
Aug 2024	170	7	6
Sep 2024	227	10	9
Total	7383	1535	779